Independent research highlights Bioxytran's clinical-stage antiviral platform, stroke program, and long-term growth potential.
BOSTON, Nov. 22, 2022 — Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics for viral diseases, hypoxia, and other significant unmet medical needs, today announced that Avise Analytics has resumed independent research coverage of the Company.
In its report, Avise Analytics assigned a fair value estimate of $2.71 per share using a discounted cash flow (DCF) methodology and highlighted Bioxytran's differentiated scientific platform, advancing clinical pipeline, and experienced leadership team.
The independent report evaluates Bioxytran's lead development programs, including ProLectin-M, the Company's investigational galectin antagonist for viral diseases, and BXT-25, its investigational oxygen therapeutic being developed to address tissue hypoxia associated with ischemic injury.
The complete independent research report is available through Avise Analytics.
Among the key observations in the report is Bioxytran's continued progress in developing ProLectin-M, an investigational oral galectin antagonist designed to interfere with viral entry by targeting galectin-mediated biological pathways.
The report notes encouraging clinical findings observed during the Company's early clinical development program, including rapid viral clearance in patients with mild-to-moderate COVID-19. Based on these results, the analyst discusses the potential for ProLectin-M to differentiate itself through its mechanism of action and favorable clinical profile as development advances.
Rather than targeting viral replication after infection has occurred, ProLectin-M is designed to interfere with viral attachment and entry into host cells through galectin modulation. Bioxytran believes this host-directed mechanism may support broader antiviral applications that warrant continued clinical investigation.
The independent research also highlights BXT-25, Bioxytran's investigational oxygen therapeutic platform.
BXT-25 is being developed to improve oxygen delivery during conditions characterized by tissue hypoxia, including acute ischemic stroke. Unlike conventional blood transfusion products, the platform is designed to function as an oxygen carrier that may be administered in settings where rapid oxygen delivery could help reduce tissue injury. The technology remains investigational and has not been approved for clinical use.
The report identifies the significant unmet medical need associated with stroke treatment and discusses the potential future impact of therapies capable of extending opportunities for intervention beyond current treatment limitations.
Avise Analytics also recognized the experience of Bioxytran's leadership team, including Chief Executive Officer David Platt, PhD, whose background in carbohydrate chemistry and biotechnology has guided the Company's platform development strategy.
Bioxytran continues to focus on advancing proprietary carbohydrate-based therapeutics through translational research, clinical development, and intellectual property expansion across multiple therapeutic areas.
Bioxytran's development strategy extends beyond individual product candidates.
The Company is building a portfolio of investigational platform technologies centered on:
These scientific platforms are being investigated across multiple disease categories, including viral infections, inflammatory disorders, fibrosis, degenerative diseases, and ischemic injury.
By focusing on disease mechanisms that influence multiple therapeutic areas, Bioxytran aims to create technologies capable of supporting future pipeline expansion while addressing significant unmet medical needs.
Bioxytran, Inc. is a clinical-stage biotechnology company developing investigational carbohydrate-based therapeutics designed to address viral diseases, inflammation, fibrosis, hypoxia, and other serious medical conditions.
The Company's research platform combines glycovirology, galectin biology, carbohydrate chemistry, and oxygen therapeutic technologies to investigate novel approaches for treating diseases where current therapies remain limited. Bioxytran's lead investigational programs include ProLectin-M, a galectin antagonist being studied for viral diseases, and BXT-25, an investigational oxygen therapeutic platform designed to improve oxygen delivery during tissue hypoxia.
This news release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding Bioxytran's investigational product candidates, scientific platforms, clinical development programs, future regulatory activities, and potential therapeutic applications. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Factors that may affect future results include clinical trial outcomes, regulatory decisions, funding availability, commercialization efforts, and other risks described in the Company's filings with the U.S. Securities and Exchange Commission. Bioxytran undertakes no obligation to update forward-looking statements except as required by law.
Bioxytran, Inc.
Website: www.bioxytraninc.com
Investor Contact:
David Platt, PhD
Chief Executive Officer
Bioxytran, Inc.
617-484-1199
info@bioxytraninc.com
